Efficacy of semi-allogeneic cytokines induced killer in treatment of non-small cell lung cancer during survival period: A 3-year follow up study
-
-
Abstract
Objective To investigate the survival effect of advanced non-small cell lung cancer treating with semi-allogeneic cytokines induced killer cells (CIK). Methods Clinical data about 47 patients with advanced non-small cell lung cancer admitted to Chinese PLA General Hospital from 2010 to 2013 were retrospectively analyzed. The patients were divided into two groups, 24 cases of observation group and 23 cases of control group. The observation group received semi-allogeneic CIK cells combined with chemotherapy while the control group was treated with chemotherapy only. Survival time and immune state of the two groups were compared. Results After treatment, the percentage of CD3+, CD3+CD56+, CD3+CD56+CD8+ cell in peripheral blood of the observation group was significantly higher (P<0.05) than that of the control group. The median progression free survival (PFS) and 1-year survival rate of observation group was significantly higher than that of the control group (7.3 months vs 5.3 months, 66.7% vs 41.4%, P<0.001). Conclusion Semi-allogeneic CIK cells combined with chemotherapy in the treatment of non-small cell lung cancer can improve the patients' immune status and prolong patients' survival period effectively.
-
-